...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Maintenance immunosuppression use and the associated risk of avascular necrosis after kidney transplantation in the United States.
【24h】

Maintenance immunosuppression use and the associated risk of avascular necrosis after kidney transplantation in the United States.

机译:在美国,维持免疫抑制疗法的使用以及肾移植术后无血管坏死的相关风险。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Avascular necrosis (AVN) after renal transplantation has been largely attributed to the use of corticosteroids. However, other risk factors such as microvascular thrombosis and hyperlipidemia have been well described and may be of increased importance in the era of early steroid cessation and avoidance. We hypothesized that maintenance immunosuppressive medications known to be associated with these risk factors for AVN would also be associated with a higher risk of AVN. METHODS: By using the U.S. Renal Data System database, we studied 27,772 primary patients on Medicare who received a solitary kidney transplant between January 1, 1996, and July 31, 2000. Cox proportional hazards regression models were used to calculate adjusted hazard ratios (AHRs) for patient- and transplant-related factors (including allograft rejection) with Medicare claims for AVN. The intensity and duration of corticosteroid use could not be assessed. RESULTS: Among patients who were prescribed sirolimus at discharge, 3.5% of patients who received the combination of sirolimus-cyclosporine A (CsA) demonstrated AVN, compared with 1.4% of patients who received the combination of sirolimus-tacrolimus (P=0.06 by chi). In Cox regression, CsA use (vs. tacrolimus) (AHR 1.36, 95% confidence interval, 1.09-1.71) was independently associated with an increased risk of AVN. Sirolimus use showed a trend toward significance (AHR 1.59, 95% confidence interval, 0.99-2.56), with no significant interaction with CsA. CONCLUSIONS: Compared with other maintenance immunosuppression, AVN was significantly more common after use of CsA prescribed at the time of discharge for renal transplantation. Whether this increased risk of AVN was directly attributable to hyperlipidemia, microvascular thrombosis, or differences in corticosteroid dosing could not be determined.
机译:背景:肾移植后的血管坏死(AVN)在很大程度上归因于皮质类固醇的使用。但是,其他危险因素,例如微血管血栓形成和高脂血症,已经被很好地描述,并且在早期停用和避免类固醇激素的时代可能越来越重要。我们假设已知与这些AVN危险因素相关的维持性免疫抑制药物也将与AVN的较高危险性相关。方法:通过使用美国肾脏数据系统数据库,我们研究了1996年1月1日至2000年7月31日接受独立肾脏移植的27,772例Medicare原发患者。使用Cox比例风险回归模型计算调整后的风险比(AHRs) )与患者和移植相关的因素(包括同种异体移植排斥)以及Medicare对AVN的索赔。无法评估使用皮质类固醇的强度和持续时间。结果:在出院时开具西罗莫司处方的患者中,接受西罗莫司-环孢霉素A(CsA)组合的患者中有3.5%表现出AVN,而接受西罗莫司-他克莫司组合的患者中有1.4%(P = 0.06) )。在Cox回归中,使用CsA(相对于他克莫司)(AHR 1.36,95%置信区间,1.09-1.71)与AVN风险增加独立相关。西罗莫司的使用呈显着趋势(AHR 1.59,95%置信区间0.99-2.56),与CsA无显着相互作用。结论:与其他维持性免疫抑制相比,AVN在肾脏移植出院时使用处方的CsA后明显更为常见。无法确定这种增加的AVN风险是否直接归因于高脂血症,微血管血栓形成或皮质类固醇剂量的差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号